Risk factors
Pasithea Therapeutics (KTTA) risk factors
Item 1A of every Pasithea Therapeutics Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors43 risks2 dropped9 reworded
Net losses increased to $20.4 million in 2025, bringing the accumulated deficit to $70.0 million. Received a Nasdaq minimum bid price deficiency notice on February 20, 2026. Added references to the OBBBA tax legislation.
Filed Mar 30, 2026 - FY2024 10-K risk factors45 risks
Clinical stage biotechnology company with operating losses and an accumulated deficit of $49.6 million.
Filed Mar 24, 2025